Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion.

In a phase 1 dose escalation study, 13 subjects with hemophilia A received by peripheral intravenous infusion a retroviral vector carrying a B-domain-deleted human factor VIII (hFVIII) gene. Infusions were well tolerated. Tests for replication competent retrovirus have been negative. Polymerase chain reaction (PCR) analyses demonstrate the persistence of vector gene sequences in peripheral blood mononuclear cells in 3 of 3 subjects tested. Factor VIII was measured in serial samples using both a one-stage clotting assay and a chromogenic assay. While no subject had sustained FVIII increases, 9 subjects had FVIII higher than 1% on at least 2 occasions 5 or more days after infusion of exogenous FVIII, with isolated levels that ranged from 2.3% to 19%. Pharmacokinetic parameters of exogenous FVIII infused into subjects 13 weeks after vector infusion showed an increased half-life (T1/2; P <.02) and area under the curve (AUC, P <.04) compared with prestudy values. Bleeding frequency decreased in 5 subjects compared with historical rates. These results demonstrate that this retroviral vector (hFVIII(V)) is safe and, in some subjects, persists more than a year in peripheral blood mononuclear cells, with measurable factor VIII levels and with increased available FVIII activity (increased T1/2 and AUC) after infusion of exogenous FVIII concentrate.

[1]  E. Check.  Second cancer case halts gene-therapy trials , 2003, Nature.

[2]  J. Knight.  Meeting aims to find brain's benchmarks for beauty , 2003, Nature.

[3]  Christof von Kalle,et al.  A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. , 2003, The New England journal of medicine.

[4]  A. Batorova,et al.  Continuous infusion of coagulation factors , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  M. Gore,et al.  Purified herpes simplex virus thymidine kinase retroviral particles: , 2002, Cancer Gene Therapy.

[6]  J. Nemunaitis,et al.  Toxicity assessment of intratumoral injection of the herpes simplex type I thymidine kinase gene delivered by retrovirus in patients with refractory cancer. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  G. White,et al.  Gene Therapy in Hemophilia: Clinical Trials Update , 2001, Thrombosis and Haemostasis.

[8]  E G Tuddenham,et al.  The hemophilias--from royal genes to gene therapy. , 2001, The New England journal of medicine.

[9]  D. Treco,et al.  Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. , 2001, The New England journal of medicine.

[10]  D. Jolly,et al.  Factors affecting long-term expression of a secreted transgene product after intravenous administration of a retroviral vector. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  M. Ragni.  New‐generation recombinant factor concentrates: bridge to gene therapy , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  K. High.  Gene therapy: a 2001 perspective , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[13]  I. Peake.  Gene therapy for haemophilia? , 2001 .

[14]  K. Boekelheide,et al.  Analysis of testes and semen from rabbits treated by intravenous injection with a retroviral vector encoding the human factor VIII gene: no evidence of germ line transduction. , 2000, Human gene therapy.

[15]  D. Lillicrap.  Hemophilia treatment. Gene therapy, factor VIII antibodies and immune tolerance: hopes and concerns. , 2000, Haematologica.

[16]  J. Nemunaitis,et al.  Long-term follow-up of retroviral vector-administered interferon-γ (IFN-γ) gene in metastatic melanoma , 2000, Cancer Gene Therapy.

[17]  A. Batorova,et al.  Intermittent injections vs. continuous infusion of Factor VIII in haemophilia patients undergoing major surgery , 2000, British journal of haematology.

[18]  S. Chang,et al.  Generation of retroviral packaging and producer cell lines for large-scale vector production and clinical application: improved safety and high titer. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  T. VandenDriessche,et al.  Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice. , 2000, Human gene therapy.

[20]  Alan McClelland,et al.  Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.

[21]  J. Nemunaitis,et al.  Long-term follow-up of retroviral vector-administered interferon-gamma (IFN-gamma) gene in metastatic melanoma. , 2000, Cancer gene therapy.

[22]  J. Lusher.  Gene therapy for hemophilia A and B: patient selection and follow-up, requirements for a cure. , 1999, Thrombosis and haemostasis.

[23]  T. Dubensky,et al.  The Resistance of Retroviral Vectors Produced from Human Cells to Serum Inactivation In Vivo and In Vitro Is Primate Species Dependent , 1999, Journal of Virology.

[24]  D. Jolly,et al.  Animal Testing of Retroviral-Mediated Gene Therapy for Factor VIII Deficiency , 1999, Thrombosis and Haemostasis.

[25]  S. Cai,et al.  Intramuscular injection of an adenoviral vector expressing hepatocyte growth factor facilitates hepatic transduction with a retroviral vector in mice. , 1999, Human gene therapy.

[26]  P. Briand,et al.  Amphotropic retroviral vectors displaying hepatocyte growth factor-envelope fusion proteins improve transduction efficiency of primary hepatocytes. , 1998, Human gene therapy.

[27]  D. Kohn,et al.  Increased gene transfer into human CD34+ progenitor cells using retroviral vectors produced by a canine packaging cell line. , 1998, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  C. Kessler,et al.  In vivo recovery with products of very high purity — assay discrepancies , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[29]  D. Jolly,et al.  Human immunodeficiency virus immunotherapy using a retroviral vector. , 1998, Current topics in microbiology and immunology.

[30]  E. Berntorp.  Second Generation, B-Domain Deleted Recombinant Factor VIII , 1997, Thrombosis and Haemostasis.

[31]  M. van den Berg,et al.  The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability , 1995, Thrombosis and Haemostasis.

[32]  E. Tuddenham,et al.  Gene therapy for the haemophilias. , 1995, Gene therapy.

[33]  M. Manco‐Johnson,et al.  Results of secondary prophylaxis in children with severe hemophilia , 1994, American journal of hematology.

[34]  H. Pettersson,et al.  Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B , 1992, Journal of internal medicine.

[35]  T. Palmer,et al.  Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. Miller,et al.  Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection , 1990, Molecular and cellular biology.

[37]  E. Wenzel,et al.  Measurement of factor VIII procoagulant antigen in normal subjects and in hemophilia A patients by an immunoradiometric assay and by an enzyme-linked immunosorbent assay. , 1987, Haemostasis.

[38]  M. Blombäck,et al.  Clinical Application of a Chromogenic Substrate Method for Determination of Factor VIII Activity , 1985, Thrombosis and Haemostasis.

[39]  D. Green,et al.  Proceedings: A more uniform measurement of factor VIII inhibitors. , 1975, Thrombosis et diathesis haemorrhagica.